Apokyn Related Published Studies
Well-designed clinical trials related to Apokyn (Apomorphine)
Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. [2011.01]
Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. [2009.05]
Apomorphine nodules in Parkinson's disease: best practice considerations. [2008.10]
Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction. [2008.09]
Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. [2008.03]
Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study. [2008.02]
Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. [2008]
Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial. [2007.12.15]
Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. [2007.12.11]
Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial. [2007.12]
Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial. [2007.09.25]
Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction--an open, randomized cross-over study with flexible dosing. [2007.02.26]
Betamethasone does not prevent nausea and vomiting induced by the dopamine-agonist apomorphine. [2006.04]
Comparison of the effect of sildenafil and apomorphine SL on nocturnal erections in healthy volunteers: a placebo-controlled study. [2005.04]
Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment. [2005.01.03]
Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men. [2005.01]
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. [2004.09]
Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study. [2004.06]
An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. [2004.06]
Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder. [2004.05]
Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. [2003.08]
Apomorphine-induced brain modulation during sexual stimulation: a new look at central phenomena related to erectile dysfunction. [2003.06]
Effects of visual sexual stimuli and apomorphine SL on cerebral activity in men with erectile dysfunction. [2003.04]
Brain activation patterns during video sexual stimulation following the administration of apomorphine: results of a placebo-controlled study. [2003.04]
The apomorphine test: a biological marker for heroin dependence disorder? [2002.10]
A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction. [2002.03]
Combination therapy for erectile dysfunction: a randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hydrochloride in men with moderate to severe erectile dysfunction. [2002.02]
Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates. [2001.10.01]
A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. [2001.09]
Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. [2001.05]
The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia. [2001.03]
Effect of apomorphine on motor and cognitive function in melancholic patients: a preliminary report. [2000.12.27]
Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group. [2000.07]
Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. [2000.01.25]
Electroencephalographic characterization of brain dopaminergic stimulation by apomorphine in healthy volunteers. [1999]
Growth hormone response to placebo, apomorphine and growth hormone releasing hormone in abstinent alcoholics and control subjects. [1998.09.01]
A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease. [1998.09]
Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. [1998.03]
Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease. [1997.12]
Apomorphine induced alteration in corneofundal potentials in depression. [1997.07]
A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease. [1996.11]
Acute challenge with apomorphine in Huntington's disease: a double-blind study. [1995.10]
Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. [1995.08.15]
Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. [1995.07]
The apomorphine test in heroin addicts. [1995.06]
Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. [1995.06]
The influence of propofol on vomiting induced by apomorphine. [1995.05]
Video assessment of yawning induced by sublingual apomorphine in migraine. [1994.10]
A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease. [1993.09]
Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease. [1993.04]
Apomorphine test for dopaminergic responsiveness: a dose assessment study. [1993.04]
Low-dose apomorphine challenge in tardive akathisia. [1993.03]
Selective effects of low doses of apomorphine on spatiotemporal contrast sensitivity in healthy volunteers: a double-blind placebo-controlled study. [1991.11]
Apomorphine-induced blinking and yawning in healthy volunteers. [1990.11]
The effect of apomorphine on regional cerebral blood flow in schizophrenia. [1989.09]
Well-designed clinical trials possibly related to Apokyn (Apomorphine)
Emerging analgesic drugs for Parkinson's disease. [2012]
Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials. [2009.03]
Induction of tolerance of dopaminergic responses in man. [2008.08]
Growth hormone response to different consecutive stress stimuli in healthy men: is there any difference? [2007.06]
[Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)] [2007]
Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study. [2004.01]
Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease. [2003.06]
Lisuride, a dopamine D2 receptor agonist, and anticraving drug expectancy as modifiers of relapse in alcohol dependence. [2002.02]
Dopaminergic sensitivity and prediction of antidepressant response. [2000.06]
Dopaminergic and cholinergic control of arginine-vasopressin secretion in type I diabetic men. [1995.06]
Fluctuations in Parkinson's disease. Pathogenetic significance of levodopa's cerebral pharmacokinetics and pharmacodynamics. [1995]
Effect of the placebo control condition in neuroendocrine challenge studies. [1994.06]
Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial. [1988]
Other research related to Apokyn (Apomorphine)
Lesions of the entopeduncular nucleus in rats prevent apomorphine-induced deficient sensorimotor gating. [2011.07.07]
A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. [2011.04]
Chronic dizocilpine or apomorphine and development of neuropathy in two rat models I: behavioral effects and role of nucleus accumbens. [2011.03]
Chronic dizocilpine or apomorphine and development of neuropathy in two animal models II: effects on brain cytokines and neurotrophins. [2011.03]
Apomorphine treatment in Alzheimer mice promoting amyloid-beta degradation. [2011.02]
Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine. [2011.02]
Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. [2011.02]
Using the self-administration of apomorphine and cocaine to measure the pharmacodynamic potencies and pharmacokinetics of competitive dopamine receptor antagonists. [2011.01.15]
Effect of magnesium chloride on psychomotor activity, emotional status, and acute behavioural responses to clonidine, d-amphetamine, arecoline, nicotine, apomorphine, and L-5-hydroxytryptophan. [2011.01]
Adolescent chronic apomorphine treatment impairs latent inhibition and reduces prefrontal cortex mGluR5 receptor expression in adult rats. [2010.12.15]
[Cutaneous necrosis at apomorphine injection points]. [2010.11]
Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug. [2010.10.08]
Apomorphine reduces subthalamic neuronal entropy in parkinsonian patients. [2010.10]
Inhalation device allows novel administration of apomorphine in men with erectile dysfunction-efficacy and safety findings. [2010.04]
Effect of apomorphine on cognitive performance and sensorimotor gating in humans. [2010.01]
Continuous subcutaneous apomorphine for severe disorders of consciousness after traumatic brain injury. [2010]
Inhalation device allows novel administration of apomorphine in men with erectile
dysfunction-efficacy and safety findings. [2010]
Behavioral sensitization to dopaminergic inhibitory and stimulatory effects induced by low vs. high dose apomorphine treatments: an unconventional dose and response reversal sensitization challenge test reveals sensitization mechanisms. [2009.12.01]
Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. [2009.12]
The pragmatic use of apomorphine at the end of life. [2009.12]
Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. [2009.12]
Electrophysiological actions of the dopamine agonist apomorphine in the paraventricular nucleus during penile erection. [2009.11.20]
Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. [2009.10.03]
Effects of cannabinoids infused into the dorsal hippocampus upon memory formation in 3-days apomorphine-treated rats. [2009.10]
Development and evaluation of perfluorocarbon nanobubbles for apomorphine delivery. [2009.10]
Biphasic effect of apomorphine, an anti-parkinsonian drug, on bladder function in rats. [2009.09.15]
The effects of apomorphine on visual perception in patients with Parkinson disease and visual hallucinations: a pilot study. [2009.09]
Low dose apomorphine induces context-specific sensitization of hypolocomotion without conditioning: support for a new state dependent retrieval hypothesis of drug conditioning and sensitization. [2009.08]
Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. [2009.06]
Human biodistribution and dosimetry of the D2/3 agonist 11C-N-propylnorapomorphine (11C-NPA) determined from PET. [2009.05]
The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease. [2009.04.15]
Apomorphine in the treatment of Parkinson disease and other movement disorders. [2009.04]
Effect of sublingual medication of sildenafil citrate/ apomorphine on sexual behaviour of male rats. [2009.04]
|
